Effects of highly active antiretroviral therapy on the survival of hiv-infected adult patients in urban slums of Kenya
Samuel Opondo Muhula, Memiah Peter, Biadgilign Sibhatu and 2 more
The Pan African Medical Journal · 2015
doi:10.11604/pamj.2015.20.63.4865 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Recent improvements in access to Anti-Retroviral Therapy (ART) have radically reduced hospitalizations and deaths associated with HIV infection in both developed countries and sub-Saharan Africa. Not much is known about survival of patients on ART in slums. The objective of this study is to identify factors associated with mortality among adult patients on ART in resource poor, urban, sub-Saharan African setting. Prospective open cohort study conducted with adult patients on ART at a clinic in Kibera slums, Nairobi, Kenya. The patients enrollment to care was between March 2005 and November 2011. Descriptive statistics were computed and Kaplan-Meier (KM) methods used to estimate survival time while Cox's proportional hazards (CPH) model fitted to determine mortality predictors. A total of 2,011 adult patients were studied, 69% being female. Female gender (p=0.0016), zidovudine-based regimen patients (p=0.0001), CD4 count 351 patients (p=0.0001), WHO stage I patients (p=0.0001) and ''Working'' functional status patients recorded better survival probability on ART. In CPH analysis, the hazard of dying was higher in patients on Stavudine-based regimen(hazard ratio (HR) =1.8; 95% CI, 1.5-2.2; p=0.0001),CD4 count =50 cells/l (HR=1.6; 95% CI, 1.5-1.7;p=0.0001), WHO Stage IV at ART initiation (HR=1.3; 95% CI, 1.1-1.6; p=0.016) and bedridden patients (HR=2.7; 95% CI, 1.7-4.4;p=0.0001). There was increased mortality among the males, those with advanced Immunosuppression, late WHO stage and bedridden patients. The findings further justify the need to switch patients on Stavudine-based regimen as per the WHO recommendations.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.